Literature DB >> 29939083

Avelumab: is it time to get excited?

Ariel E Marciscano1, James L Gulley1, Howard L Kaufman2,3.   

Abstract

Entities:  

Keywords:  Antibody-dependent cell-mediated cytotoxicity (ADCC); anti-PD-L1; avelumab; immune checkpoint blockade; immune checkpoint inhibitor; immunotherapy

Mesh：

Substances：

Year:  2018        PMID： 29939083      PMCID： PMC8232371          DOI： 10.1080/14737140.2018.1493380

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  15 in total

1.  ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Authors:  Caroline Jochems; James W Hodge; Massimo Fantini; Kwong Y Tsang; Amanda J Vandeveer; James L Gulley; Jeffrey Schlom
Journal:  Int J Cancer       Date:  2017-05-19       Impact factor: 7.396

2.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

3.  Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

Authors:  Sandra P D'Angelo; Jeffery Russell; Céleste Lebbé; Bartosz Chmielowski; Thilo Gambichler; Jean-Jacques Grob; Felix Kiecker; Guilherme Rabinowits; Patrick Terheyden; Isabella Zwiener; Marcis Bajars; Meliessa Hennessy; Howard L Kaufman
Journal:  JAMA Oncol       Date:  2018-09-13       Impact factor: 31.777

4.  Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Authors:  Benjamin Boyerinas; Caroline Jochems; Massimo Fantini; Christopher R Heery; James L Gulley; Kwong Yok Tsang; Jeffrey Schlom
Journal:  Cancer Immunol Res       Date:  2015-05-26       Impact factor: 11.151

5.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

Review 6.  The FDA Oncology Center of Excellence and precision medicine.

Authors:  Kirsten B Goldberg; Gideon M Blumenthal; Amy E McKee; Richard Pazdur
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-06

7.  Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.

Authors:  Jonathan K Fallon; Amanda J Vandeveer; Jeffrey Schlom; John W Greiner
Journal:  Oncotarget       Date:  2017-03-28

8.  Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Authors:  Andrea B Apolo; Jeffrey R Infante; Ani Balmanoukian; Manish R Patel; Ding Wang; Karen Kelly; Anthony E Mega; Carolyn D Britten; Alain Ravaud; Alain C Mita; Howard Safran; Thomas E Stinchcombe; Marko Srdanov; Arnold B Gelb; Michael Schlichting; Kevin Chin; James L Gulley
Journal:  J Clin Oncol       Date:  2017-04-04       Impact factor: 44.544

9.  Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

Authors:  Renee N Donahue; Lauren M Lepone; James L Gulley; Jeffrey Schlom; Italia Grenga; Caroline Jochems; Massimo Fantini; Ravi A Madan; Christopher R Heery
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

10.  Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Authors:  Manish R Patel; John Ellerton; Jeffrey R Infante; Manish Agrawal; Michael Gordon; Raid Aljumaily; Carolyn D Britten; Luc Dirix; Keun-Wook Lee; Mathew Taylor; Patrick Schöffski; Ding Wang; Alain Ravaud; Arnold B Gelb; Junyuan Xiong; Galit Rosen; James L Gulley; Andrea B Apolo
Journal:  Lancet Oncol       Date:  2017-12-05       Impact factor: 41.316
View more
  2 in total

Review 1.  Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients.

Authors:  Romy Mosch; Henk-Jan Guchelaar
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

2.  Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.

Authors:  Joanna C Masters; Akash Khandelwal; Alessandra di Pietro; Haiqing Dai; Satjit Brar
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.